Home > Publications database > Emerging tools for the early detection of prostate cancer. > print

001     304845
005     20250925115117.0
024 7 _ |a 10.1002/bco2.70081
|2 doi
024 7 _ |a pmid:40979549
|2 pmid
024 7 _ |a pmc:PMC12446083
|2 pmc
037 _ _ |a DKFZ-2025-01951
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Haider, Muhammad
|0 0000-0001-8085-0555
|b 0
245 _ _ |a Emerging tools for the early detection of prostate cancer.
260 _ _ |a [Hoboken, NJ]
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1758723416_30917
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Prostate cancer (PCa) is the second most common cancer in men globally, with a rising incidence. Early detection through population-based screening by Prostate Specific Antigen (PSA) testing improves survival outcomes, at the expense of overdiagnosis and overtreatment of clinically insignificant disease. Here, we explore emerging tools for more effective PCa early detection and evaluate their potential roles for PCa screening.Key articles on emerging adjuncts and alternatives to PSA for PCa early detection were identified.Multiparametric MRI (mpMRI) remains the gold standard modality for identifying clinically significant PCa and has been evaluated for screening. Newer imaging strategies incorporating biparametric MRI (bpMRI) or multiparametric ultrasound (mpUS) potentially offer similar accuracy to mpMRI. Saliva-derived polygenic risk scores (PRS) hold potential as a non-invasive screening tool to identify at-risk patient groups. Blood-based biomarker tests can improve risk stratification, reducing unnecessary biopsies while maintaining detection of clinically significant cancers compared to PSA alone. Urine-based biomarker tests have been examined for the early detection and risk stratification of clinically significant disease as adjuncts to PSA testing.PSA is commonly used to detect early PCa, but its lack of specificity and associated overdiagnosis risk has led to controversy over its use for population-based screening. Imaging modalities such as mpMRI have reduced detection of clinically insignificant PCa, and emerging cost-effective alternatives, such as bpMRI and mpUS, show promise. Molecular biomarkers and PRS for risk stratification may help target imaging-based early detection more effectively to at-risk populations. Prospective randomised clinical trials are urgently needed to evaluate the performance of different modalities for population-wide screening. Future developments may involve technologies such as artificial intelligence and diagnostic tests that incorporate circulating tumour markers.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a 4 K score
|2 Other
650 _ 7 |a AI
|2 Other
650 _ 7 |a ExoDx prostate
|2 Other
650 _ 7 |a MRI
|2 Other
650 _ 7 |a MyProstateScore
|2 Other
650 _ 7 |a PRS
|2 Other
650 _ 7 |a PSA
|2 Other
650 _ 7 |a SelectMDx
|2 Other
650 _ 7 |a Stockholm 3
|2 Other
650 _ 7 |a early diagnosis
|2 Other
650 _ 7 |a polygenic risk score
|2 Other
650 _ 7 |a prostate cancer
|2 Other
650 _ 7 |a prostate health index
|2 Other
650 _ 7 |a screening
|2 Other
650 _ 7 |a ultrasound
|2 Other
700 1 _ |a Leow, Jeffrey J
|b 1
700 1 _ |a Nordström, Tobias
|0 0000-0003-4915-7546
|b 2
700 1 _ |a Mortezavi, Ashkan
|b 3
700 1 _ |a Albers, Peter
|0 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578
|b 4
|u dkfz
700 1 _ |a Heer, Rakesh
|b 5
700 1 _ |a Rajan, Prabhakar
|0 0000-0001-8064-9878
|b 6
773 _ _ |a 10.1002/bco2.70081
|g Vol. 6, no. 9, p. e70081
|0 PERI:(DE-600)3015455-8
|n 9
|p e70081
|t BJUI compass
|v 6
|y 2025
|x 2688-4526
909 C O |o oai:inrepo02.dkfz.de:304845
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-08T17:09:29Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-08T17:09:29Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2024-08-08T17:09:29Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-08-08T17:09:29Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
920 1 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C130-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21